Find public news by keyword, exact ticker, category and date.
Open a ticker page for its news coverage. The news search below stays a text search.
3 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
Korro Bio has dosed the first cohort in its Phase 1/2 clinical trial (Anchor) for KRRO-121. Dosing in UCD patients is expected to start in H1 2027, with an interim readout in H2 2027.
Korro Bio, Inc. announced that the first cohort of patients has been dosed in its Phase 1/2 clinical trial for Krro-121.
Korro Bio dosed the first healthy-volunteer cohort in its Phase 1/2 ANCHOR trial of KRRO-121 for hyperammonemia; single 2 mg/kg dose, with interim readout expected in 2H 2027 and patient dosing expected in H1 2027.